Bristol Myers Squibb has secured global rights to a pair of anti-SARS-CoV-2 antibodies discovered by The Rockefeller University. The antibodies entered phase 1 development last month, putting them well behind similar therapies from companies including Eli Lilly and Regeneron.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,